Loading…
Loading…
ARWR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for ARWR and 80,000+ other tickers.
See exactly how ARWR's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ARWR and 80,000+ other tickers.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia…
DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Risk and Volatility DBV Technologies has a beta
Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its CNS pipeline, initiating two new ARO-MAPT phase 2 trials and advancing four additional CNS candidates into the clinic by end of 2027. Recent milestones include strong Redemplo phase 3 data, positive ARO-DIMER-PA results, and FDA STAR program entry for Redemplo, supporting a robust long-term growth outlook.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals NASDAQ: ARWR presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system, alongside initial clinical results for its TRiM CNS delivery platform.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimer's disease and other tauopathies. These results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier and achieve substantial target gene knockdown in the brain.